MarketCap
Facebook
X
Telegram
Zimmer Biomet Holdings Cash Flow 2025-2006 | ZBH
Brief overview of Zimmer Biomet Holdings's cash generation
Cash flows are assessed across five available annual periods spanning 2018 to 2025.
Cash from operations ended at $1.7 billion versus $1.7 billion initially. Cash generation did not expand materially.
Operating cash flow was positive in all five observations, adding repeatability to the cash profile.
Operating cash flow to net income stands at 2.4x. Accounting results have solid cash support.
Operating cash margin was stable at 22% initially and 20.6% at the end.
Estimated working capital increased by $518.1 million, equal to 6.3% of latest revenue. More cash became tied up in receivables and inventory.
Cash flow takeaway
Zimmer Biomet Holdings retains acceptable cash resilience. Future assessment depends on cash margin, capex and debt trends.
Annual Cash Flow Zimmer Biomet Holdings
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
1.7 B | 1.5 B | 1.58 B | - | - | - | 1.59 B | 1.75 B | 1.58 B | 1.63 B | - | - | 963 M | 1.15 B | 1.18 B | 1.19 B | 1.12 B | 1.04 B | 1.08 B | - |
Depreciation & Amortization |
1.09 B | 996 M | 952 M | 926 M | 938 M | 898 M | 871 M | 1.04 B | 1.06 B | 1.04 B | 712 M | 376 M | 358 M | 363 M | 360 M | 340 M | 337 M | 275 M | 230 M | - |
Accounts Payables |
303 M | 195 M | 411 M | 354 M | 306 M | 330 M | 401 M | 363 M | 330 M | 364 M | 285 M | 167 M | 146 M | 184 M | 143 M | 130 M | 135 M | 186 M | - | - |
Accounts Receivables |
1.7 B | 1.48 B | 1.44 B | 1.38 B | 1.26 B | 1.45 B | 1.36 B | 1.28 B | 1.49 B | 1.6 B | 1.45 B | 912 M | 937 M | 885 M | 839 M | 776 M | 751 M | 733 M | - | - |
Total Inventories |
2.29 B | 2.24 B | 2.39 B | 2.15 B | 2.15 B | 2.45 B | 2.38 B | 2.26 B | 2.08 B | 1.96 B | 2.25 B | 1.17 B | 1.07 B | 995 M | 930 M | 936 M | 913 M | 928 M | - | - |
All numbers in USD currency
Quarterly Cash Flow Zimmer Biomet Holdings
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q3 | 2010-Q2 | 2010-Q1 | 2009-Q3 | 2009-Q2 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
359 M | 1.18 B | 761 M | 383 M | - | - | 228 M | - | - | 308 M | - | - | - | - | - | - | - | 246 M | - | 779 M | 398 M | 451 M | - | 1.16 B | 585 M | 284 M | - | 1.37 B | 884 M | 490 M | - | 1.18 B | 716 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 180 M | - | 784 M | 439 M | 207 M | - | 784 M | 433 M | 182 M | 852 M | 532 M | 260 M | 732 M | 380 M |
Depreciation & Amortization |
270 M | 810 M | 526 M | 254 M | 251 M | 243 M | 239 M | 145 M | 138 M | 232 M | - | 132 M | 133 M | 234 M | - | 704 M | 155 M | 236 M | - | 767 M | 509 M | 253 M | - | 752 M | 501 M | 248 M | - | 786 M | 525 M | 264 M | - | 798 M | 532 M | 268 M | - | 787 M | 499 M | 247 M | - | 428 M | 189 M | 89 M | - | 283 M | 192 M | 101 M | - | 268 M | 176 M | 85.1 M | - | 273 M | 190 M | 96.8 M | - | 266 M | 175 M | 86.1 M | 250 M | 166 M | 84.9 M | 250 M | 161 M |
Accounts Payables |
361 M | 315 M | 349 M | 301 M | 322 M | 342 M | 370 M | 320 M | 355 M | 397 M | 354 M | 334 M | - | 322 M | 306 M | 328 M | 361 M | 306 M | 282 M | 330 M | 330 M | 330 M | 401 M | 401 M | 401 M | 401 M | 363 M | 363 M | 363 M | 363 M | 330 M | 330 M | 330 M | 330 M | 364 M | 364 M | 364 M | 364 M | 285 M | 285 M | 285 M | 285 M | 145 M | 145 M | 167 M | 167 M | 146 M | 146 M | 146 M | 146 M | 184 M | 184 M | 184 M | 184 M | 143 M | 143 M | 143 M | 143 M | 116 M | 115 M | 136 M | 121 M | 144 M |
Accounts Receivables |
1.73 B | 1.6 B | 1.61 B | 1.53 B | 1.48 B | 1.42 B | 1.45 B | 1.34 B | 1.37 B | 1.38 B | 1.38 B | 1.28 B | - | 1.25 B | 1.26 B | 1.39 B | 1.42 B | 1.26 B | 1.28 B | 1.45 B | 1.45 B | 1.45 B | 1.36 B | 1.36 B | 1.36 B | 1.36 B | 1.28 B | 1.28 B | 1.28 B | 1.28 B | 1.54 B | 1.54 B | 1.54 B | 1.54 B | 1.6 B | 1.6 B | 1.6 B | 1.6 B | 1.45 B | 1.45 B | 1.45 B | 1.45 B | 912 M | 912 M | 912 M | 912 M | 937 M | 937 M | 937 M | 937 M | 885 M | 885 M | 885 M | 885 M | 839 M | 839 M | 839 M | 839 M | 758 M | 765 M | 767 M | 743 M | 769 M |
Total Inventories |
2.25 B | 2.48 B | 2.45 B | 2.24 B | 2.37 B | 2.37 B | 2.39 B | 2.32 B | 2.28 B | 2.24 B | 2.15 B | 2.13 B | - | 2.13 B | 2.15 B | 2.52 B | 2.53 B | 2.15 B | 2.17 B | 2.45 B | 2.45 B | 2.45 B | 2.38 B | 2.38 B | 2.38 B | 2.38 B | 2.26 B | 2.26 B | 2.26 B | 2.26 B | 2.07 B | 2.07 B | 2.07 B | 2.07 B | 1.96 B | 1.96 B | 1.96 B | 1.96 B | 2.25 B | 2.25 B | 2.25 B | 2.25 B | 1.19 B | 1.19 B | 1.17 B | 1.17 B | 1.07 B | 1.07 B | 1.07 B | 1.07 B | 995 M | 995 M | 995 M | 995 M | 930 M | 930 M | 930 M | 930 M | 925 M | 886 M | 896 M | 972 M | 981 M |
All numbers in USD currency
Cash Flow Statement is one of the three key financial reports of the company Zimmer Biomet Holdings, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.
Main Sections of the Cash Flow Statement- Operating Activities
This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash. - Investing Activities
Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign. - Financing Activities
Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.
The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.
Cash flow statements of other stocks in the Medical devices sector
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Cutera
CUTR
|
- | -10.19 % | $ 1.99 M |  USA |
 |
Myomo
MYO
|
$ 0.93 | -3.11 % | $ 38.9 M | USA |
 |
EDAP TMS S.A.
EDAP
|
- | - | $ 162 M |  France |
 |
Avinger
AVGR
|
- | -20.74 % | $ 369 K | USA |
 |
Axonics Modulation Technologies
AXNX
|
- | - | $ 3.31 B | USA |
 |
Eargo
EAR
|
- | - | $ 10.2 M | USA |
 |
Allied Healthcare Products
AHPI
|
- | 3.58 % | $ 2.21 M | USA |
 |
Apollo Endosurgery
APEN
|
- | - | $ 475 M | USA |
 |
Aziyo Biologics
AZYO
|
- | 1.37 % | $ 20.5 M | USA |
 |
BioSig Technologies
BSGM
|
- | 37.08 % | $ 85.7 M | USA |
 |
BIOLASE
BIOL
|
- | -13.19 % | $ 166 K | USA |
 |
Profound Medical Corp.
PROF
|
$ 7.24 | -0.14 % | $ 219 M |  Canada |
 |
AxoGen
AXGN
|
$ 41.37 | 0.53 % | $ 1.91 B | USA |
 |
Quanterix Corporation
QTRX
|
$ 3.38 | -3.15 % | $ 144 M | USA |
 |
AVITA Medical
RCEL
|
$ 4.44 | -3.69 % | $ 124 M |  Australia |
 |
Conformis
CFMS
|
- | - | $ 16.4 M | USA |
 |
Cardiovascular Systems
CSII
|
- | 0.15 % | $ 844 M | USA |
 |
Bruker Corporation
BRKR
|
$ 61.74 | -1.86 % | $ 9.37 B | USA |
 |
Smith & Nephew plc
SNN
|
$ 32.66 | 0.31 % | $ 28.3 B |  Britain |
 |
Tactile Systems Technology
TCMD
|
$ 27.4 | -1.23 % | $ 627 M | USA |
 |
Neovasc
NVCN
|
- | - | $ 111 M | Canada |
 |
Dynatronics Corporation
DYNT
|
- | 14.99 % | $ 929 K | USA |
 |
Tandem Diabetes Care
TNDM
|
$ 18.59 | 4.67 % | $ 1.26 B | USA |
 |
Second Sight Medical Products
EYES
|
- | -0.97 % | $ 54.4 M | USA |
 |
GBS
GBS
|
- | -0.57 % | $ 7.12 M | USA |
 |
ClearPoint Neuro
CLPT
|
$ 14.14 | -2.68 % | $ 400 M | USA |
 |
IRIDEX Corporation
IRIX
|
$ 0.86 | -1.95 % | $ 14.6 M | USA |
 |
Avanos Medical
AVNS
|
$ 24.99 | - | $ 1.16 B | USA |
 |
Viemed Healthcare
VMD
|
$ 11.65 | -2.27 % | $ 453 M | USA |
 |
Varex Imaging Corporation
VREX
|
$ 10.95 | -1.62 % | $ 453 M | USA |
 |
Invacare Corporation
IVC
|
- | - | $ 24.7 M | USA |
 |
Cytosorbents Corporation
CTSO
|
$ 0.35 | -4.32 % | $ 21.8 M | USA |
 |
LENSAR
LNSR
|
$ 5.25 | -1.87 % | $ 62.8 M | USA |
 |
Beyond Air
XAIR
|
$ 5.51 | 0.92 % | $ 45.7 B | USA |
 |
NanoVibronix
NAOV
|
- | - | $ 1.08 M | USA |
 |
Xtant Medical Holdings
XTNT
|
$ 0.43 | 0.14 % | $ 60 M | USA |
 |
NuVasive
NUVA
|
- | - | $ 2.07 B | USA |
 |
Natus Medical Incorporated
NTUS
|
- | 1.94 % | $ 1.05 B | USA |
 |
Nevro Corp.
NVRO
|
- | - | $ 217 M | USA |